Opinion/decision on a Paediatric investigation plan (PIP): Zoliflodacin, decision type: , therapeutic area: , PIP number: P/0381/2022

Opinion/decision on a Paediatric investigation plan (PIP): Xofluza,Baloxavir marboxil, decision type: , therapeutic area: , PIP number: P/0383/2022

Medicinal products for human use: monthly figures - August 2023

Calcium chloride dihydrate/magnesium chloride hexahydrate/malic acid/sodium acetate trihydrate/sodium chloride....potassium chloride : List of nationally authorised medicinal products - PSUSA/00010622/202301

Opinion/decision on a Paediatric investigation plan (PIP): Bismuth (subcitrate),Metronidazole (benzoate),Tetracycline (hydrochloride), decision type: , therapeutic area: , PIP number: P/0371/2022

Opinion/decision on a Paediatric investigation plan (PIP): Benlysta,belimumab, decision type: , therapeutic area: , PIP number: P/0395/2022

Opinion/decision on a Paediatric investigation plan (PIP): Veyvondi,vonicog alfa, decision type: , therapeutic area: , PIP number: P/0363/2022

Human medicines European public assessment report (EPAR): Strimvelis, autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence, Severe Combined Immunodeficiency, Date of authorisation: 26/05/2016, Revision: 9, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Olumiant,Baricitinib, decision type: , therapeutic area: , PIP number: P/0364/2022

Opinion/decision on a Paediatric investigation plan (PIP): Vocabria,Cabotegravir, decision type: , therapeutic area: , PIP number: P/0396/2022